Andrew Hertler, MD, FACP
As the chief medical officer of Evolent, Dr. Andrew Hertler is responsible for the advancement of the company's clinical quality and value-based strategy, utilization management policies and clinical thought leadership initiatives. A practicing board-certified oncologist for 30 years, he is a nationally recognized leader in oncology clinical practice. Dr. Hertler has volunteered on a number of American Society of Clinical Oncology (ASCO) committees, including the Clinical Practice, Quality of Care and Payment Reform Committees, as well as the Quality Oncology Practice Initiative Certification Program Oversight Council.
-
Bending the Oncology Cost Curve in 2023 and Beyond
Our chief medical officer shares three trends likely to impact oncology drug spend in the near future.
Read Article
-
A 'Pink Tax' in Oncology?
Evolent addresses a startling difference in what men and women pay for the same drug.
Read Article
-
Loading More...